401 related articles for article (PubMed ID: 16432188)
1. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.
Haghighi K; Kolokathis F; Gramolini AO; Waggoner JR; Pater L; Lynch RA; Fan GC; Tsiapras D; Parekh RR; Dorn GW; MacLennan DH; Kremastinos DT; Kranias EG
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1388-93. PubMed ID: 16432188
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes.
Posch MG; Perrot A; Geier C; Boldt LH; Schmidt G; Lehmkuhl HB; Hetzer R; Dietz R; Gutberlet M; Haverkamp W; Ozcelik C
Heart Rhythm; 2009 Apr; 6(4):480-6. PubMed ID: 19324307
[TBL] [Abstract][Full Text] [Related]
3. The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.
Haghighi K; Pritchard T; Bossuyt J; Waggoner JR; Yuan Q; Fan GC; Osinska H; Anjak A; Rubinstein J; Robbins J; Bers DM; Kranias EG
J Mol Cell Cardiol; 2012 Mar; 52(3):773-82. PubMed ID: 22155237
[TBL] [Abstract][Full Text] [Related]
4. DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters.
Stege NM; Eijgenraam TR; Oliveira Nunes Teixeira V; Feringa AM; Schouten EM; Kuster DWD; van der Velden J; Wolters AHG; Giepmans BNG; Makarewich CA; Bassel-Duby R; Olson EN; de Boer RA; Silljé HHW
Circ Res; 2023 Dec; 133(12):1006-1021. PubMed ID: 37955153
[TBL] [Abstract][Full Text] [Related]
5. Leducq Transatlantic Network of Excellence to Cure Phospholamban-Induced Cardiomyopathy (CURE-PLaN).
Doevendans PA; Glijnis PC; Kranias EG
Circ Res; 2019 Sep; 125(7):720-724. PubMed ID: 31513489
[TBL] [Abstract][Full Text] [Related]
6. Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy.
Kumar M; Haghighi K; Koch S; Rubinstein J; Stillitano F; Hajjar RJ; Kranias EG; Sadayappan S
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768995
[TBL] [Abstract][Full Text] [Related]
7. Early consequences of the phospholamban mutation PLN-R14del
Maniezzi C; Eskandr M; Florindi C; Ferrandi M; Barassi P; Sacco E; Pasquale V; Maione AS; Pompilio G; Teixeira VON; de Boer RA; Silljé HHW; Lodola F; Zaza A
Acta Physiol (Oxf); 2024 Mar; 240(3):e14082. PubMed ID: 38214033
[TBL] [Abstract][Full Text] [Related]
8. A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia.
Liu GS; Morales A; Vafiadaki E; Lam CK; Cai WF; Haghighi K; Adly G; Hershberger RE; Kranias EG
Cardiovasc Res; 2015 Jul; 107(1):164-74. PubMed ID: 25852082
[TBL] [Abstract][Full Text] [Related]
9. Aberrant PLN-R14del Protein Interactions Intensify SERCA2a Inhibition, Driving Impaired Ca
Vafiadaki E; Haghighi K; Arvanitis DA; Kranias EG; Sanoudou D
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805951
[TBL] [Abstract][Full Text] [Related]
10. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human.
Haghighi K; Kolokathis F; Pater L; Lynch RA; Asahi M; Gramolini AO; Fan GC; Tsiapras D; Hahn HS; Adamopoulos S; Liggett SB; Dorn GW; MacLennan DH; Kremastinos DT; Kranias EG
J Clin Invest; 2003 Mar; 111(6):869-76. PubMed ID: 12639993
[TBL] [Abstract][Full Text] [Related]
11. Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy.
Feyen DAM; Perea-Gil I; Maas RGC; Harakalova M; Gavidia AA; Arthur Ataam J; Wu TH; Vink A; Pei J; Vadgama N; Suurmeijer AJ; Te Rijdt WP; Vu M; Amatya PL; Prado M; Zhang Y; Dunkenberger L; Sluijter JPG; Sallam K; Asselbergs FW; Mercola M; Karakikes I
Circulation; 2021 Aug; 144(5):382-392. PubMed ID: 33928785
[TBL] [Abstract][Full Text] [Related]
12. Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition.
Schmitt JP; Ahmad F; Lorenz K; Hein L; Schulz S; Asahi M; Maclennan DH; Seidman CE; Seidman JG; Lohse MJ
Circulation; 2009 Jan; 119(3):436-44. PubMed ID: 19139388
[TBL] [Abstract][Full Text] [Related]
13. Deletion of DWORF does not affect cardiac function in aging and in PLN-R14del cardiomyopathy.
Stege NM; Oliveira Nunes Teixeira V; Zijlstra SN; Feringa AM; de Boer RA; Silljé HHW
Am J Physiol Heart Circ Physiol; 2024 Mar; 326(3):H870-H876. PubMed ID: 38334971
[TBL] [Abstract][Full Text] [Related]
14. Arrhythmia Mechanism and Dynamics in a Humanized Mouse Model of Inherited Cardiomyopathy Caused by Phospholamban R14del Mutation.
Raad N; Bittihn P; Cacheux M; Jeong D; Ilkan Z; Ceholski D; Kohlbrenner E; Zhang L; Cai CL; Kranias EG; Hajjar RJ; Stillitano F; Akar FG
Circulation; 2021 Aug; 144(6):441-454. PubMed ID: 34024116
[TBL] [Abstract][Full Text] [Related]
15. A study in Polish patients with cardiomyopathy emphasizes pathogenicity of phospholamban (PLN) mutations at amino acid position 9 and low penetrance of heterozygous null PLN mutations.
Truszkowska GT; Bilińska ZT; Kosińska J; Śleszycka J; Rydzanicz M; Sobieszczańska-Małek M; Franaszczyk M; Bilińska M; Stawiński P; Michalak E; Małek ŁA; Chmielewski P; Foss-Nieradko B; Machnicki MM; Stokłosa T; Ponińska J; Szumowski Ł; Grzybowski J; Piwoński J; Drygas W; Zieliński T; Płoski R
BMC Med Genet; 2015 Apr; 16():21. PubMed ID: 25928149
[TBL] [Abstract][Full Text] [Related]
16. Isoform changes of action potential regulators in the ventricles of arrhythmogenic phospholamban-R14del humanized mouse hearts.
Rogalska ME; Vafiadaki E; Erpapazoglou Z; Haghighi K; Green L; Mantzoros CS; Hajjar RJ; Tranter M; Karakikes I; Kranias EG; Stillitano F; Kafasla P; Sanoudou D
Metabolism; 2023 Jan; 138():155344. PubMed ID: 36375644
[TBL] [Abstract][Full Text] [Related]
17. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy.
Eijgenraam TR; Boukens BJ; Boogerd CJ; Schouten EM; van de Kolk CWA; Stege NM; Te Rijdt WP; Hoorntje ET; van der Zwaag PA; van Rooij E; van Tintelen JP; van den Berg MP; van der Meer P; van der Velden J; Silljé HHW; de Boer RA
Sci Rep; 2020 Jun; 10(1):9819. PubMed ID: 32555305
[TBL] [Abstract][Full Text] [Related]
18. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy.
Karakikes I; Stillitano F; Nonnenmacher M; Tzimas C; Sanoudou D; Termglinchan V; Kong CW; Rushing S; Hansen J; Ceholski D; Kolokathis F; Kremastinos D; Katoulis A; Ren L; Cohen N; Gho JMIH; Tsiapras D; Vink A; Wu JC; Asselbergs FW; Li RA; Hulot JS; Kranias EG; Hajjar RJ
Nat Commun; 2015 Apr; 6():6955. PubMed ID: 25923014
[TBL] [Abstract][Full Text] [Related]
19. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation.
Medin M; Hermida-Prieto M; Monserrat L; Laredo R; Rodriguez-Rey JC; Fernandez X; Castro-Beiras A
Eur J Heart Fail; 2007 Jan; 9(1):37-43. PubMed ID: 16829191
[TBL] [Abstract][Full Text] [Related]
20. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del-Related Cardiomyopathy.
Eijgenraam TR; Boogerd CJ; Stege NM; Oliveira Nunes Teixeira V; Dokter MM; Schmidt LE; Yin X; Theofilatos K; Mayr M; van der Meer P; van Rooij E; van der Velden J; Silljé HHW; de Boer RA
Circ Heart Fail; 2021 Nov; 14(11):e008532. PubMed ID: 34587756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
